Mitapivat
AG348-C-020
Phase 3 small_molecule active
Quick answer
Mitapivat for Sickle Cell Disease is a Phase 3 program (small_molecule) at AGIOS PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- AGIOS PHARMACEUTICALS, INC.
- Indication
- Sickle Cell Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active